#United States #Cambridge #Infection Prevention #Next Gen Diagnostics #Genomic Detection

Introduction

Next Gen Diagnostics (NGD) is taking a significant step in the healthcare landscape by introducing its new branch, NGD Infection Prevention, set to commence operations on January 1. This spinoff aims to focus on implementing real-time genomic transmission detection technology specifically tailored for U.S. hospitals. The decision reflects an increasingly recognized need for advanced methods to control infections effectively in hospital environments.

The Need for Innovation

According to Dr. Paul A. Rhodes, CEO of NGD, the healthcare sector is at a pivotal moment. The ability to utilize low-cost, highly automated sequencing and bioinformatics technologies has matured to a point where it can be effectively integrated into hospital practices. "Most hospital transmissions currently go undetected," he underscores, signaling a growing gap in existing infection control methodologies. The evidence suggests that missed transmissions occur even in the most carefully monitored areas, such as neonatal intensive care units.

With multiple peer-reviewed studies supporting the necessity of innovative solutions, NGD is now prepared to deploy its detection systems across hospitals in the U.S. and Israel. "Our approach will allow hospitals to identify and mitigate transmission in real-time, reducing both human and financial costs associated with hospital-acquired infections," Dr. Rhodes explains.

Deployment of Technology

NGD Infection Prevention will roll out its flagship NGD200 system, designed to process 48 bacterial samples with minimal hands-on time required from hospital staff. This streamlined operation is crucial for hospitals aiming to maintain efficiency while improving patient safety. Additionally, the NGD EpiAssist automates the bioinformatics processes involved in detection, delivering actionable insights to healthcare providers overnight, further enhancing the operational workflow.

Anticipated Outcomes

Looking ahead, Samantha Kahn, Director of Strategic Partnerships for NGD Infection Prevention, hinted at further announcements in the upcoming year, including a publication detailing the impact of sequence-based detection within hospitals grappling with antibiotic-resistant infections. Reduction in average length of stay and prevention of adverse patient outcomes are both expected benefits from the new implementation – a crucial factor as hospitals strive to improve patient care outcomes.

The Role of Education and Support

As NGD embarks on its mission to implement genomic transmission detection at scale, the focus will shift from mere technology development to effective communication with clients. Dr. Rhodes emphasizes the importance of successful deployment and exemplary support across the 7,300 U.S. hospitals, 16,000 nursing homes, and 7,000 dialysis centers. The compelling financial implications of avoided patient events and enhanced patient safety will likely incentivize healthcare systems and regulators to adopt these advanced technologies.

Conclusion

The formation of NGD Infection Prevention represents a crucial advancement in the battle against hospital-acquired infections. By embracing genomic sequencing technologies, the healthcare sector may very well transform its approach to infection control. With a lab located in Cambridge, MA, and a subsidiary in Israel, NGD Infection Prevention aims to become a leading force in enhancing real-time infection control measures in medical facilities nationwide. This promising initiative reflects the increasing recognition of the critical role that real-time data and innovative technologies will play in shaping a safer future for patient care.